{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:36:33Z","timestamp":1773365793605,"version":"3.50.1"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:sec id=\"ab-ooi250047-4\"><jats:title>Importance<\/jats:title><jats:p>Sclerotherapy involves injecting a sclerosing agent into the nasal, oral mucosa, and cutaneous telangiectasias to reduce bleeding, demonstrating both safety and efficacy as a treatment. Despite its proven benefits, few physicians currently offer this therapy to patients with hereditary hemorrhagic telangiectasia (HHT).<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi250047-5\"><jats:title>Objective<\/jats:title><jats:p>To promote the safe use of sclerotherapy among patients with HHT.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi250047-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>In this survey study, a modified Delphi protocol was used to achieve consensus on sclerotherapy among a panel of 6 experts. The Delphi consensus took place through online meetings and surveys sent via Google Forms. Six experts from Italy, Spain, and the US, each with more than 10 years of experience in the use of sclerotherapy for HHT-associated epistaxis and cutaneous telangiectasias, participated in the Delphi protocol.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi250047-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>This approach included 3 rounds of ratings interspersed with an in-person discussion led by an experienced moderator to resolve disagreements. Experts in using specific sclerotherapy agents (sodium tetradecyl sulfate and polidocanol), both in liquid or foam form, participated in surveys. Consensus was defined as agreement among 4 of 6 panelists. After discussions and clarifications, 3 survey rounds were conducted, resulting in consensus on all 30 statements across 7 domains.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi250047-8\"><jats:title>Results<\/jats:title><jats:p>The consensus among 6 experts indicates that stable patients with HHT are eligible for sclerotherapy, with individualized precautions based on medical history and comorbidities. In-office sclerotherapy provides several advantages, including quick access, high patient satisfaction, and the elimination of general anesthesia risks, despite the occasional occurrence of vasovagal events and moderate bleeding. According to the 2015 European Society of Cardiology guideline, antibiotic prophylaxis is recommended for patient preparation, while fasting is generally not necessary. Specific precautions for preventing complications such as septal perforation and amaurosis were identified. Adverse effects are usually mild to moderate, with severe bleeding being rare. Practitioners should have expertise in endoscopy or rhinoscopy, thorough pathology knowledge, and training from experienced professionals.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi250047-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this survey study, the consensus of 6 experts produced 30 statements guiding patient care and safe procedure implementation. While not formal treatment guidelines, these statements offer valuable insights for clinicians seeking to adopt or align with expert recommendations. Further validation and research are encouraged to ensure these consensus statements improve patient care and outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2025.2296","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:31:17Z","timestamp":1754580677000},"page":"881","source":"Crossref","is-referenced-by-count":1,"title":["Consensus on Sclerotherapy for Patients With Hereditary Hemorrhagic Telangiectasia\u2013Related Epistaxis"],"prefix":"10.1001","volume":"151","author":[{"given":"Paolo","family":"Farneti","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Ospedale Bellaria, Dip. Chirurgie Specialistiche, AUSL Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol","family":"Marcos-Salazar","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Crocione","sequence":"additional","affiliation":[{"name":"HHT Italia\u2013Associazione di Promozione Sociale, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Boyer","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Minnesota, Minneapolis"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Puxeddu","sequence":"additional","affiliation":[{"name":"Unit of Otorhinolaryngology, Department of Surgery, Azienda Ospedaliero-Universitaria di Cagliari, University of Cagliari, Cagliari, Italy"},{"name":"Unit of Otorhinolaryngology, Department of Surgery, King\u2019s College Hospital London-Dubai, Dubai, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan B.","family":"Whitehouse","sequence":"additional","affiliation":[{"name":"Otolaryngology HHT Center of Excellence Medical College of Georgia, Augusta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay F.","family":"Piccirillo","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Washington University in St Louis School of Medicine, St Louis, Missouri"},{"name":"Editor, JAMA Otolaryngology\u2013Head & Neck Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"ooi250047r1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/JBM.S45295","article-title":"Optimal management of hereditary hemorrhagic telangiectasia.","volume":"2014","author":"Kumar","year":"2014","journal-title":"J Blood Med"},{"issue":"5","key":"ooi250047r2","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/lary.23893","article-title":"Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia.","volume":"123","author":"Silva","year":"2013","journal-title":"Laryngoscope"},{"issue":"4","key":"ooi250047r3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/alr.20053","article-title":"Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study.","volume":"1","author":"Boyer","year":"2011","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"ooi250047r4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4193\/Rhino11.142","article-title":"Local sclerotherapy with polydocanol (Aethoxysklerol) for the treatment of epistaxis in Rendu-Osler-Weber or hereditary hemorrhagic telangiectasia (HHT): 15 years of experience.","volume":"50","author":"Morais","year":"2012","journal-title":"Rhinology"},{"issue":"5","key":"ooi250047r5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/alr.21287","article-title":"Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu).","volume":"4","author":"Hanks","year":"2014","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"ooi250047r6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/alr.21484","article-title":"Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia.","volume":"5","author":"Boyer","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"ooi250047r7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.21053\/ceo.2015.00416","article-title":"Comparison of local sclerotherapy with lauromacrogol versus nasal packing in the treatment of anterior epistaxis.","volume":"9","author":"Farneti","year":"2016","journal-title":"Clin Exp Otorhinolaryngol"},{"issue":"10","key":"ooi250047r8","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/lary.27930","article-title":"Sclerotherapy and topical nasal propranolol: an effective and safe therapy for HHT-epistaxis.","volume":"129","author":"Esteban-Casado","year":"2019","journal-title":"Laryngoscope"},{"issue":"1","key":"ooi250047r9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/00034894221078075","article-title":"Sclerotherapy for hereditary hemorrhagic telangiectasia-related epistaxis: a systematic review.","volume":"132","author":"Thiele","year":"2023","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"ooi250047r10","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1456686","article-title":"Innovations in the management of epistaxis secondary to hereditary hemorrhagic telangiectasia: our evolution to injection sclerotherapy as the treatment of choice.","volume":"5","author":"Kumar","year":"2024","journal-title":"Front Allergy"},{"issue":"7","key":"ooi250047r11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.7326\/L21-0067","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.","volume":"174","author":"Faughnan","year":"2021","journal-title":"Ann Intern Med"},{"issue":"17","key":"ooi250047r12","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.3390\/jcm10173845","article-title":"Sclerotherapy on demand with polidocanol to treat HHT nosebleeds.","volume":"10","author":"Marcos","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"ooi250047r13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11695-017-3070-2","article-title":"The first consensus statement on one anastomosis\/mini gastric bypass (OAGB\/MGB) using a modified Delphi approach.","volume":"28","author":"Mahawar","year":"2018","journal-title":"Obes Surg"},{"issue":"6","key":"ooi250047r16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1177\/0268355513483280","article-title":"European guidelines for sclerotherapy in chronic venous disorders.","volume":"29","author":"Rabe","year":"2014","journal-title":"Phlebology"},{"issue":"4","key":"ooi250047r17","first-page":"277","article-title":"2015 ESC Guidelines for the management of infective endocarditis.","volume":"17","author":"Habib","year":"2016","journal-title":"G Ital Cardiol (Rome)"},{"issue":"5","key":"ooi250047r18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/lary.29701","article-title":"Sclerotherapy versus cautery\/laser treatment for epistaxis in hereditary hemorrhagic telangiectasia.","volume":"132","author":"Woodard","year":"2022","journal-title":"Laryngoscope"},{"issue":"1","key":"ooi250047r19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/jcm12010313","article-title":"Ophthalmic complications after needle-based medical aesthetic procedures: a narrative review.","volume":"12","author":"Boninska","year":"2022","journal-title":"J Clin Med"},{"key":"ooi250047r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100848","article-title":"Iatrogenic ophthalmic artery occlusion and retinal artery occlusion.","volume":"78","author":"Lee","year":"2020","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"ooi250047r21","first-page":"E65","article-title":"Vascular complications after facial filler injection: a literature review and meta-analysis.","volume":"12","author":"Sito","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"issue":"7","key":"ooi250047r22","first-page":"233","article-title":"Unilateral blindness following injection of aethoxysklerol into the nasal septum with medico-legal consequences.","volume":"31","author":"Breuninger","year":"1983","journal-title":"HNO"},{"issue":"7","key":"ooi250047r23","first-page":"236","article-title":"Unilateral blindness following intranasal aethoxysklerol injection.","volume":"31","author":"Uffenorde","year":"1983","journal-title":"HNO"},{"issue":"8","key":"ooi250047r24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4103\/0301-4738.191508","article-title":"Orbital infarction syndrome after multiple percutaneous sclerotherapy sessions for facial low-flow vascular malformation: a case report and literature review.","volume":"64","author":"Sio","year":"2016","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"ooi250047r25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/ICB.0000000000000559","article-title":"Blind-sided by cosmetic vein sclerotherapy: a case ophthalmic arterial occlusion.","volume":"13","author":"Arunakirinathan","year":"2019","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"ooi250047r26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1186\/s12886-023-03128-4","article-title":"Topical injection of sclerosant to treat cheek subcutaneous venous malformation resulting in blindness: a case report.","volume":"23","author":"Cui","year":"2023","journal-title":"BMC Ophthalmol"},{"issue":"12","key":"ooi250047r27","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1517\/13543780903376163","article-title":"Polidocanol for endovenous microfoam sclerosant therapy.","volume":"18","author":"Eckmann","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"ooi250047r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2024.104537","article-title":"Treatment of hereditary hemorrhagic telangiectasias with sclerotherapy: a case series.","volume":"46","author":"Ji","year":"2025","journal-title":"Am J Otolaryngol"},{"key":"ooi250047r14","volume-title":"Clinical Practice Guideline Development: Methodology Perspectives","author":"Brook","year":"1995"},{"key":"ooi250047r15","unstructured":"Fitch? K, Bernstein? SJ, Aguilar? MD, . The RAND\/UCLA Appropriateness Method user\u2019s manual. RAND Corporation; 2001. Accessed March 22, 2025. https:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2837313\/jamaotolaryngology_farneti_2025_oi_250047_1756834546.42371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:00:34Z","timestamp":1757602834000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2837313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2025.2296","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}